Conditions: Pediatric Plaque Psoriasis
Keywords: Immunex Amgen Pediatric, plaque psoriasis clinical trial
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 182
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

Detailed description:
This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).

Arms:
arm 1: Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.

Interventions: intervention 1: Etanercept
Intervention descriptions: intervention 1: Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection

Protocol document: